Swoboda, David M. http://orcid.org/0000-0002-6102-1695
Ali, Najla Al
Chan, Onyee http://orcid.org/0000-0003-2872-1961
Padron, Eric
Kuykendall, Andrew T.
Song, Jinming
Hussaini, Mohammad
Talati, Chetasi http://orcid.org/0000-0002-2246-213X
Sweet, Kendra
Lancet, Jeffrey E. http://orcid.org/0000-0002-7751-7310
Sallman, David A. http://orcid.org/0000-0003-0504-8233
Komrokji, Rami S. http://orcid.org/0000-0002-1876-5269
Article History
Received: 21 August 2020
Revised: 9 September 2020
Accepted: 25 October 2020
First Online: 1 November 2020
Compliance with ethical standards
:
: DMS, NAA, OC, JS, and MH declare no conflict of interest. EP obtains research funding from Incyte, Kura Oncology and BMS and has received Honorari a from Novartis. ATK is on advisory boards for Blueprint Medicines, Novartis and Prelude and has been part of a speaker’s bureau for BMS. CT is on advisory boards for Abbvie, Celgene, Pfizer, BMS and Novartis and has been part of a speaker’s bureau for Astellas, BMS and Jazz. KS is on advisory committees for Takeda, BMS, Novartis, Agios. She has received research funding from Incyte and has received Honoraria from Stemline and Astellas. JEL has done consulting for AbbVie, Agios, Astella, Daiichi Sankyo, ElevateBio, Jazz and received Honoria from Agios. DAS has received research funding from Celgene and Jazz and done consulting for Celyad, Incyte, Novartis, Agios, BMS, Intellia, Kite and Syndax. RSK has been part of a speaker’s bureau for Jazz, BMS and Agios and received honoraria from Abbvie, Incyte, Acceleron, Novartis and Geron.